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Monotherapeutic options for carbapenem resistant infections are limited. Studies
suggest that combination therapy may be associated with better outcomes than
monotherapies. However, this is still controversial. This study assessed, the efficacy
of combination therapy against carbapenem resistant Enterobacteriaceae harboring
singly various extended spectrum beta lactamase or carbapenemase encoding genes.
Thus, four isolates harboring either blaCTXM−15, blaCTXM 15 and bla− OXA−48, blaNDM−1,
or blaKPC 2 genes were selected for testing. Minimal inhibitory concentration was−
determined by broth dilution method. Gene transcript levels on single and combined
treatments were done in vitro and in vivo by qRT-PCR. Assessment of treatments
was done in BALB/c mice according to a specific protocol. As such, the qRT-PCR
revealed a significant decrease of transcript levels in all isolates upon using rifampicin
or tigecycline, singly or in combination with colistin. However, variable levels were
obtained using colistin singly or in combination with meropenem or fosfomycin. In vivo
assessment showed that all combinations used were effective against isolates harboring
blaCTXM 15, blaOXA 48, and blaNDM 1. Conversely, the most significant combination− − −
against the isolate harboring blaKPC 2 gene was colistin with either carbapenem,−
fosfomycin, or kanamycin. As a conclusion, combination therapy selected based on
the type of carbapenemase produced, appeared to be non-toxic and might be effective
in BALB/c mice. Therefore, the use of a rationally optimized combination therapy might
lead to better results than monotherapy, however, clinical trials are needed for human
consumption.
Keywords: Enterobacteriaceae, carbapenem resistance, carbapenemase, in vivo, combination therapy, gene
transcript
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Introduction
During the past decade, the emergence of multidrug resistant
Enterobacteriaceae, namely the third generation cephalosporins
increased signiﬁcantly (Nordmann et al., 2012), leading to the
use of carbapenems that represent the primary treatment of
choice for such infections (El-Srougy et al., 2012; Nordmann
et al., 2012). Nevertheless, the overuse of these antimicrobial
agents led to the development of carbapenem resistance (El-
Herte et al., 2012; Nordmann et al., 2012; Baroud et al.,
2013), such as the resistance by broad-spectrum beta-lactamase
production (such as CTX-M or AmpC enzymes) in conjunction
with eﬄux pump or outer membrane impermeabilities (such
as OmpC/OmpF) and/or the production of carbapenemases
(such as KPC-2, OXA-48, or NDM-1 enzymes; Nordmann
et al., 2012; Tängdén, 2012; Baroud et al., 2013; Satlin et al.,
2014). Most antibacterial agents cross the outer membrane
of bacteria through the OmpF and OmpC porin proteins;
this holds true for the Enterobacteriaceae family and the
β-lactams as well (Pagès et al., 2008; Delcour, 2009; Tsai
et al., 2011). Since the β-lactams enter through these porins,
it is easily understandable that when the porin permeability
decreases, the entry of the β-lactams would decrease as well.
Impermeability results when the porin expression is modiﬁed,
attributable to a decrease in the level of expression of a
porin, or a mutation in the porin channel resulting in its
non-functionality (Pagès et al., 2008). As a result in the
decreased entrance of the β-lactams to the inner cellular
space, decreased susceptibility ranges for cephalosporins and
carbapenems in Enterobacteriaceae can occur. Carbapenem
resistance is often associated with resistance to other classes of
antimicrobial agents (Tängdén, 2012), narrowing the treatment
options against these multi-drug resistant bacteria. Subsequently,
treatment alternatives are limited to colistin, tigecycline,
rifampicin, and fosfomycin. (El-Herte et al., 2012; El-Srougy
et al., 2012; Tängdén, 2012; Perez and Van Duin, 2013;
van Duin et al., 2013). Reports of associated nephro/neuro-
toxicity (El-Srougy et al., 2012; Perez and Van Duin, 2013;
Satlin et al., 2014), and increased emergence of resistance
(Lim et al., 2011; Tängdén, 2012; Satlin et al., 2014) marked
their use as controversial and not recommended, especially
when used as monotherapy (Lim et al., 2011; Tängdén, 2012).
It is currently debatable whether using these antibacterial
agents in combination therapy is more advantagous than
monotherapy.
Diﬀerent studies emphasize the importance of using these
antimicrobial agents in combination therapy to overcome
carbapenem resistance (El-Herte et al., 2012; El-Srougy et al.,
2012; Tängdén, 2012; van Duin et al., 2013) especially with
limited of prospects in developing new antimicrobial agents
(Kmeid et al., 2013), however, the results are still controversial
(Tängdén, 2012; Kmeid et al., 2013; Satlin et al., 2014).
This study attempted to assess the eﬀect of combination
therapy, both in vitro and in vivo, in order to recommend
potential establishment of eﬀective regimens against carbapenem
resistance in Enterobacteriaceae. In addition, we attempted to
assess the transcript levels of the carbapenem resistance encoding
genes in response to various selected treatment options, in vitro
and in vivo, in order to determine whether certain carbapenemase
encoding genes are inducible by the administered antimicrobial
agents singly or in combination.
Materials and Methods
Clinical Isolates
Two carbapenem resistant Klebsiella pneumoniae isolates (IMP33
and IMP216) harboring respectively the blaCTXM−15 and
blaNDM−1 and one carbapenem resistant Escherichia coli isolate
(IMP53) harboring the blaOXA−48 gene along with blaCTXM−15
gene, obtained from clinical specimens at a tertiary care facility
in Beirut, Lebanon, were used in this study (Baroud et al., 2013).
A fourth isolate, a Salmonella spp. (KPC) harboring the blaKPC−2
gene, from the Centers for Disease Control and Prevention
(CDC) was also included.
Animal Testing
BALB/c mice were used in this study. All BALB/c mice were
obtained from the Animal Care Facility of the University after
the approval of the Institutional Animal Care andUse Committee
(IACUC). A total number of 416 adult female BALB/c mice,
ranging between 6 and 8 weeks-old and weighing between
20 and 30 g, were used. The mice were handled according
to “Guide for the Care and Use of Laboratory Animals”
(National Research Council [USA], 2011). A total of 80 mice
(20 mice/isolate) were used to determine the LD50 for each
of the isolates IMP33 (blaCTX−M−15), IMP53 (blaCTX−M−15
and blaOXA−48), IMP216 (blaNDM−1), and KPC (blaKPC−2)
as described by Nowotny (1971). A total of 48 mice were
used for the detection of gene transcript levels on single and
combined treatments in vivo by qRT-PCR. And ﬁnally a total
of 288 was used for the assessment of combination therapy in
vivo.
Bacterial Identification and Susceptibility
Testing
Conﬁrmation of the isolates to the species level was performed
by API20E kit (Biomérieux, SA13280 Marcy-l’Etoile, France).
Antimicrobial susceptibility testing by minimum inhibitory
concentration (MIC) was performed by the broth dilution
method, and were interpreted according to the Clinical and
Laboratory Standards Institute (CLSI) guidelines Clinical
and Laboratory Standards Institute [CLSI] (2013), for
imipenem, ertapenem, meropenem, fosfomycin, kanamycin, and
ceftazidime. Whereas, colistin and tigecycline were interpreted
according to the (The European Committee on Antimicrobial
Susceptibility Testing [EUCAST], 2014). E. coli ATCC 25922
served as a quality control strain.
Polymerase Chain Reaction
Genomic DNA extraction of the four isolates was performed
using the Illustra Bacteria Genomic Prep Mini Spin Kit
(GE Healthcare, UK), according to the manufacturer’s
instructions and Baroud et al. (2013). The four isolates
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were tested for the presence of blaTEM−1, blaCTX−M−15,
blaOXA−48, blaNDM−1, blaKPC−2, omp-C, and omp-F. The
primers (Thermo Scientiﬁc, Inc., USA) are as follows: TEM-1
Primer: F: 5′-ATGAGTATTCAACATTTCCG-3′, R: 5′-CCAATG
CTTAATGAGTGAGG-3′, with an amplicon size of 836 base
pair (bp). OMP-C Primer: F: 5′-GTTAAAGTACTGTCCCTCCT
G-3′, R: 5′-GAACTGGTAAACCAGACCCAG-3′, with an
amplicon size of 1086 bp. OMP-F Primer: F: 5′-CAGGTACTGCA
AACGCTGC-3′, R: 5′-GTCAACATAGGTGGACATG-3′, with
an amplicon size of 953 bp. OXA-48 Primer: F: 5′-TTGGTG
GCATCGATTATCGG-3′, R: 5′-GAGCACTTCTTTTGTGATG
GC-3′, with an amplicon size of 744 bp. NDM-1 Primer: F:
5′-GGAAACTGGCGACCAACG-3′, R: 5′-ATGCGGGCCGTAT
GAGTGA-3′, with an amplicon size of 678 bp. CTX-M-15
Primer: F: 5′-GGTTAAAAAATCACTGCGTC-3′, R: 5′-TTAC
AAACCGTCGGTGACGA-3′, with an amplicon size of 874 bp.
KPC-2 Primer: F: 5′-GCAGCGGCAGCAGTTTGTTGATT-3′, R:
5′-GTAGACGGCCAACACAATAGGTGC-3′, with an amplicon
size of 184 bp. Amplicons were detected by gel electrophoresis,
on 1.5% agarose gel (Seakem LE agarose, Lonza, USA), stained
with ethidium bromide (Amresco, USA), visualized under UV
illumination (Transilluminator, Haakebuchler Instruments, Inc.,
USA) using Olympus digital camera and Digi-Doc Program
(UVP, CA, UK).
Quantitative Reverse Transcription PCR
On In Vitro Samples
For in vitro samples, for each isolate diﬀerent conditions were
tested, and in each tube: the bacterial suspension (grown in TSB)
was used either alone, or added to either the MIC concentration
of colistin, rifampicin, tigecycline, or meropenem respectively, or
the MIC concentration of colistin, in combination with the MIC
concentration of the former antimicrobial agents. The samples
were adjusted to have the same bacterial concentrations in all the
tubes, a total of 3.33 × 105 CFU/ml. After 18 h of incubation,
RNA extraction was performed.
On In Vivo Samples
A total number of 48 adult female BALB/c mice was used
for this part of the experiment. For the in vivo experiments,
four diﬀerent protocols for each of the four isolates was
used, having 3 mice/protocol. Each mouse was injected with
3x LD50 dose. Mice were injected with either the bacterial
suspension alone or the bacterial suspension in addition to either
the MIC dose of colistin alone, or the MIC dose of colistin
in combination with the MIC dose of either meropenem or
fosfomycin. All bacterial injections were given at time zero, while
the treatment was given 1 h post-infection. All injections were
given intraperitoneally. After 4 h from the antimicrobial agent
injection(s), all the mice were euthanized, dissected, and blood
was collected by cardiac puncture. The tubes were centrifuged at
800 g for 20 min at 4◦C; serum was collected and the RNA was
extracted.
RNA extraction for both the in vitro and in vivo samples
were done using the Illustra RNA spin Mini RNA Isolation
Kit (GE healthcare, UK) according to the manufacturer’s
instructions. Synthesis of cDNA by the QuantiTect R© Reverse
Transcription Kit (QIAGEN, Germany) from the extracted
RNA was used in the quantitative Reverse Transcription
PCR (q-RT PCR) using BioRad CFX96 Real Time System,
C1000 Thermal Cycler (Germany). The QuantiFastTM SYBER R©
green PCR kit (Qiagen, Germany) was used (according to the
manufacturer’s instructions) to examine the relative expression
of the genes of interest, in vitro and in vivo, in response to the
diﬀerent treatment options. The primers (Thermo Scientiﬁc,
Ulm, Germany) for the genes blaCTXM−15 (Xu et al., 2005),
blaOXA−48 (Swayne et al., 2011), blaNDM−1 (Zheng et al., 2013),
and blaKPC−2 (Swayne et al., 2011) are as previously described.
The primers (Thermo Scientiﬁc, Inc., USA) used are: CTX-
M-15: Forward Primer: 5′-GCGTGATACCACTTCACCTC-3′,
Reverse Primer: 5′- TGAAGTAAGTGACCAGAATC-3′,
with an amplicon size of 260 bp. OXA-48: Forward Primer:
5′-TTCGGCCACGGAGCAAATCAG-3′, Reverse Primer: 5′-
GATGTGGGCATATCCATATTCATCGCA-3′, with an amplicon
size of 240 bp. NDM-1 Primer: Forward Primer: 5′-TTGGCG
ATCTGGTTTTCC-3′, Reverse Primer: 5′- GGTTGATCTCCTG
CTTGA-3′, with an amplicon size of 195 bp. KPC-2: Forward
Primer: 5′-GCAGCGGCAGCAGTTTGTTGATT-3′, Reverse
Primer: 5′-GTAGACGGCCAACACAATAGGTGC-3′, with
an amplicon size of 184 bp. rpoB (reference gene): Forward
Primer: 5′-TCGAAACGCCTGAAGGTC-3′, Reverse Primer:
5′- TTGGAGTTCGCCTGAGC-3′, with an amplicon size of
184 bp. The Bio Rad CFXmanager software was used to calculate
the ratio of transcription level of the respective treatment used
to the transcription level of the bacterial suspension alone
for each gene in question for its respective isolate, employing
the rpoB gene as a standard. As a note, the value for each
condition is not the quantity of expression, rather it is the
relative expression compared to the control, with the control
being 1. Therefore, any value less than 1 is considered to be
a reduced expression, while any value above 1 is considered
as increased expression. The relative value, is automatically
calculated by the software where the value of each condition
(which is the use of the diﬀerent antimicrobial agents) is
divided by the value of the control (which is in this case
the positive control), that is why this value does not have a
unit.
Each sample was run in triplicates for both the housekeeping
gene (rpoB), which is the control gene, and the gene in
inquiry (blaCTXM−15, blaOXA−48 and blaCTXM−15, blaNDM−1,
and blaKPC−2) in their respective isolates. The qRT-PCR
conditions were: 1 cycle of 95◦C for 15 min, 45 cycles of:
95◦C for 10 s, Ta (Annealing Temperature) for 30 s, and 72◦C
for 20 s.
Mice Observations
A total of 80 mice (20 mice/isolate) were used to determine
the LD50 for each of the isolates IMP33 (blaCTX−M−15), IMP53
(blaCTX−M−15 and blaOXA−48), IMP216 (blaNDM−1), and KPC
(blaKPC−2).
To determine the eﬃcacy of combination therapy in vivo
the bacterial concentration used for the injections was 3x
LD50 for the respective isolate. The in vivo-MIC equivalent
doses were (Rahal et al., 2011), according to this formula:
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Antimicrobial agent in vivoMIC dose (μg) =
[Antimicrobial agent in vitroMIC (μg/ μl) ×
in vitroMIC broth volume (μl) × concentration
(CFU) of the isolate administered in vivo]
[concentration (CFU) of the isolate per in vitroMIC reaction] ;
as these were the concentrations of the antimicrobial agents to
be injected in the mice. The antimicrobial agents used for the in
vivo assessment were: colistin sulfate salt, ceftazidime hydrate,
meropenem trihydrate, kanamycin sulfate, tigecycline hydrate
(Sigma-Aldrich, Co., St. Louis, MO, USA), ertapenem sodium,
imipenem monohydrate (Merck & CO., Inc., West Point, PA,
USA), and fosfomycin disodium (abcam Biochemicals). There
by, 288 mice were divided into four major groups (Groups I–IV)
according to the injected bacteria (IMP33, IMP53, IMP216, or
KPC respectively). Furthermore, each major group was divided
into 12 subgroups (6 mice/subgroup), in order to assess the
eﬃcacy of each treatment with the respective bacteria. All
injections were given intraperitoneally. Two sub-groups in each
major group served as control. Sub-group 1 received only a
TSB injection (at time zero) and served as a negative control.
While sub-group 2 received the bacterial injection alone and
served as a positive control. Bacterial injections were given
for subgroups 2–12 (at time zero). Subsequently in vivo-MIC
doses of single (colistin or rifampicin) or combined (colistin
with either, ertapenem, imipenem, meropenem, ceftazidime,
tigecycline, rifampicin, kanamycin, or fosfomycin) treatments
were given after 1 h post-infection. The monitoring period was
10 days, and the mice were observed for weight loss and survival
rate. Blood collected from dead mice was cultured, and API was
performed to conﬁrm the cause of the death being the respective
bacterial injections.
Statistical Analysis
Statistical analysis was performed for qRT-PCR by unpaired t-test
using the Graph-Pad t-test calculator. Additionally, the Kaplan–
Meier plot was used to estimate the survival rates. p-values< 0.05
were considered to be statistically signiﬁcant.
Results
In Vitro Antimicrobial Susceptibility and PCR
Profiles of the Four Isolates
The results of antimicrobial susceptibility proﬁles as determined
by MIC, while gene distribution by PCR for each of the four
isolates are presented in Tables 1 and 2 respectively.
Quantitative Reverse Transcription PCR
On In Vitro Samples
The in vitro assessment of the eﬀect of combination therapy on
gene transcript levels by qRT-PCR, revealed, in all isolates, a
decrease in the extended spectrum beta lactamase (ESBL) and
carbapenemase encoding gene transcript levels when rifampicin
and tigecycline were used individually, or in combination with
colistin. Whereby, rifampicin monotherapy or in combination
TABLE 1 | Antimicrobial susceptibility profiles of the four isolates as determined by MIC broth dilution.
Antimicrobial agents
Isolate IMP33 Klebsiella pneumoniae
(blaCTXM−15) MIC(µg/ml)
IMP53 E. coli (blaCTX−M−15
and blaOXA−48) MIC(µg/ml)
IMP216 K. pneumoniae
(blaNDM−1) MIC(µg/ml)
KPC Salmonella
(blaKPC−2) MIC(µg/ml)
Ceftazidime 128 1024 4096 128
Ertapenem 2 32 512 4
Meropenem 0.125 4 64 4
Imipenem 2 8 1024 4
Fosfomycin 4096 512 >1024 256
Kanamycin 64 128 >16384 32
Tigecycline 8 0.5 4 0.5
Colistin 2 2 128 2
Rifampicin 32 8 128 8
MIC, minimum inhibitory concentration.
TABLE 2 | Gene distribution in the four isolates as determined by PCR.
Gene
Isolate IMP33 K. pneumonia
(blaCTXM−15)
IMP53 E. coli (blaCTX−M−15
and blaOXA−48)
IMP216 K. pneumonia
(blaNDM−1)
KPC Salmonella
(blaKPC−2)
blaTEM−1 + + + +
blaCTX−M−15 + + − −
blaOXA−48 − + − −
blaNDM−1 − − + −
blaKPC−2 − − − +
omp-C + + − +
omp-F − + + −
“+”, positive result; “−”, negative result.
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with colistin, in vitro, led to the most noticeable decrease in the
gene transcript levels of blaCTX−M−15, blaOXA−48, blaNDM−1, and
blaKPC−2. Also, Tigecycline monotherapy or in combination with
colistin, in most of the isolates, resulted in a signiﬁcant decline
in the carbapenemase gene transcript levels. The combination
of tigecycline and colistin appears to lower carbapenemase
transcript levels than their respective monotherapies. The in vitro
transcript levels of the ESBL and carbapenemase encoding genes,
for the respective isolates harboring the various genes are shown
in Figure 1.
On In Vivo Samples
The in vivo assessment of the eﬀect of combination therapy
on gene transcript levels by qRT-PCR revealed, in most of
the isolates, diﬀerent responses when compared to their
respective in vitro responses. Moreover, when colistin was used
singly or in combination with meropenem or fosfomycin
in vivo, the qRT-PCR showed variable gene transcript
levels for the respective ESBL and carbapenemase encoding
genes within the in vivo samples. The transcript levels
of the ESBL and carbapenemase encoding genes, for the
respective isolates harboring the various genes are shown in
Figure 2.
Mice Observations
In Vivo: LD50
The LD50 of the four isolates IMP33(blaCTXM−15), IMP53
(blaCTXM−15 and blaOXA−48), IMP216 (blaNDM−1), and KPC
(blaKPC−2) was determined to be 5.62× 105, 1 × 107, 1.47× 107,
and 1 × 108 CFU respectively.
Assessment of the Efficacy of Treatments In Vivo
After the 10-days monitoring period, all the mice in negative
control sub-groups (no bacteria injected) survived the
monitoring period. On the other hand, the survival rate in
the positive control sub-groups (only bacteria injected) was
33% for Group I injected with isolate IMP33 (blaCTX−M−15),
0% in Group II injected with isolate IMP53 (blaCTXM−15 and
blaOXA−48), 83% for Group III injected with isolate IMP216
(blaNDM−1), whereas 0% in Group IV injected with isolate KPC
(blaKPC−2), respectively.
As for the sub-groups (3–12) in both Groups I and III, injected
with isolates IMP33 (blaCTX−M−15) and IMP216 (blaNDM−1)
respectively, which received an injection of antimicrobial agents
singly or in combination, a 100% survival rate was observed. On
the other hand, the sub-groups (3–12) in Group II, injected with
isolate IMP53 (blaCTXM−15 and blaOXA−48) was 80%. While the
FIGURE 1 | Gene transcript levels in vitro for the genes blaCTX−M−15, blaCTX−M−15 and blaOXA−48, blaNDM−1, blaKPC−2 in their respective isolates
IMP33, IMP53, IMP216, and KPC treated with Colistin, Meropenem, Rifampicin, Tigecycline, Colistin+Meropenem, Colistin+Fosfomycin,
Colistin+Rifampicin, or Colistin+Tigecycline at the MIC levels. IMP33: colistin: 4.94 (p = 0.025), meropenem: 15.54 (p = 0.376), rifampicin: 0 (p = 0.002),
tigecyclin: 0.07 (p = 0.038), colistin and meropenem: 16.95 (p = 0.012), colistin and fosfomycin: 9.87 (p = 0.487), colistin and rifampicin: 0 (p = 0.001), colistin and
tigecycline: 0 (p = 0.025). IMP53 (CTX-M-15): colistin: 7.44 (p = 0.042), meropenem: 4.31 (p = 0.026), rifampicin: N/A, tigecyclin: N/A, colistin and meropenem:
0.28 (p = 0.068), colistin and fosfomycin: 0.69 (p = 0.049), colistin and rifampicin: 0.01 (p = 0.037), colistin and tigecycline: N/A. IMP53 (OXA-48): colistin: 0
(p = 0.875), meropenem: 0.36 (p = 0.746), rifampicin: N/A, tigecyclin: 0.04 (p = 0.001), colistin and meropenem: 5.14 (p = 0.041), colistin and fosfomycin: 14.91
(p = 0.002), colistin and rifampicin: 0 (p = 0.045), colistin and tigecycline: 0 (p = 0.001). IMP216: colistin: 10.20 (p = 0.012), meropenem: 16.79 (p = 0.046),
rifampicin: 1.47 (p = 0.049), tigecyclin 2.60 (p = 0.002), colistin and meropenem: 5.14 (p = 0.050), colistin and fosfomycin: 14.91 (p = 0.002), colistin and
rifampicin: 4.14 (p = 0.002), colistin and tigecycline: 1.38 (p = 0.372). KPC: colistin: 1.23 (p = 0.005), meropenem: 9.89 (p = 0.019), rifampicin 0.23 (p = 0.001),
tigecyclin 0.56 (p = 0.043), colistin and meropenem: 0 (p = 0.011), colistin and fosfomycin: 4.93 (p = 0.032), colistin and rifampicin: 0 (p = 0.012), colistin and
tigecycline: 0 (p = 0.048). PC, positive control; Col, colistin; Mer, meropenem; Fos, fosfomycin; Rif, rifampicin; and Tig, tigecycline.
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FIGURE 2 | Gene transcript levels in vivo for the genes blaCTX−M−15, blaCTX−M−15 and blaOXA−48, blaNDM−1, blaKPC−2 in their respective isolates
IMP33, IMP53, IMP216, and KPC treated with Colistin, Colistin+Meropenem, or Colistin+Fosfomycin at the MIC levels. IMP33: colistin: 5.40 (p = 0.053),
colistin and meropenem: 1.38 (p = 0.038), colistin and fosfomycin: 0.19 (p = 0.024). IMP53 (CTX-M-15): colistin: 0.04 (p = 0.038), colistin and meropenem: 0.41
(p = 0.029), colistin and fosfomycin: 0.19 (p = 0.096). IMP53 (OXA-48): colistin: 3.53 (p = 0.221), colistin and meropenem: 0 (p = 0.041), colistin and fosfomycin: 0
(p = 0.049). IMP216: colistin: 2.22 (p = 0.043), colistin and meropenem: 3.10 (p = 0.021), colistin and fosfomycin: 1.44 (p = 0.052). KPC: colistin: 0.53 (p = 0.026),
colistin and meropenem: 1.49 (p = 0.980), colistin and fosfomycin: 0.75 (p = 0.042). PC, positive control; Col, colistin; Mer, meropenem; Fos, fosfomycin.
lowest survival rate of 66% was observed in sub-groups (3–12),
in Group IV, injected with isolate KPC (blaKPC−2). The survival
rates according to the treatments for each of the four isolates are
shown in Figures 3A–D.
During the monitoring period, the average weight of the
mice (ﬁgures not shown) in the negative control sub-groups for
the four isolates increased, while that of the positive control
sub-groups (expect for that of Group III) decreased within the
ﬁrst 4 days. As for the other sub-groups in Groups I, II and
IV, the mice that survived showed weight regain 5-days post-
receiving the respective bacterial and treatment injections. With
regard to all the subgroups in Group III that received bacterial
injections (with or without treatment) no signiﬁcant weight
loss was observed; rather, the mice showed stability and weight
gain.
The API testing conﬁrmed that the cause of death was due to
the respective bacterial injections; i.e., K. pneumonia for isolates
IMP33 (blaCTX−M−15) and IMP216 (blaNDM−1), E. coli for isolate
IMP53 (blaCTXM−15 and blaOXA−48), and Salmonella spp. for
KPC (blaKPC−2) isolate.
Discussion
This study attempted to assess the transcript levels of the
carbapenem resistance encoding genes in response to various
selected treatment options, in vitro and in vivo, in order to
determine whether certain carbapenemase encoding genes are
inducible by the administered antimicrobial agents singly or
in combination. Based on the qRT-PCR results, rifampicin
monotherapy or in combination with colistin, in vitro, led
to the most noticeable decrease in the gene transcript levels
of blaCTX−M−15, blaOXA−48, blaNDM−1, and blaKPC−2. This
result was expected since rifampicin inhibits RNA synthesis
by inhibiting gene transcription (Rahal et al., 2011). Although
rifampicin monotherapy resulted in the most eﬃcient transcript
inhibition, its use as monotherapy is not recommended due to
the high rate of emerging resistance (Kohanski et al., 2010).
Consequently, the combination of colistin and rifampicin seems
to be a better treatment option.
Similarly, the in vitro tigecycline monotherapy or in
combination with colistin, in most of the isolates, resulted
in a signiﬁcant decline in the carbapenemase gene transcript
levels. This can be explained by the fact that tigecycline
inhibits the synthesis of proteins used in catalyzing RNA
synthesis (Herbert et al., 2001). The combination of tigecycline
and colistin appears to be more eﬀective, leading to lower
carbapenemase transcript levels than their respective
monotherapies.
In vitro and in vivo testing of colistin in combination with
either meropenem or fosfomycin, or their monotherapies, led to
diﬀerent gene transcript levels in isolates IMP33 (blaCTX−M−15),
IMP216 (blaNDM−1) and KPC(blaKPC−2), when compared to
their positive controls. This might be explained by the fact
that these antimicrobial agents do not inhibit gene transcription
like rifampicin, rather act on the bacterial cell wall, and/or
by the induction of the survival mode in bacteria to increase
the production of the hydrolyzing enzymes (El-Herte et al.,
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FIGURE 3 | (A) Percentage of survivals of Group I injected with isolate IMP33, harboring blaCTX−M−15 gene, during the monitoring period (p-value = 0.049). The
concentration of the bacteria injected (3xLD50) = 1.68 × 106 CFU/μl. Concentration of the antimicrobial agents added: COL: 6.744 μg/μl, ETP: 6.744 μg/μl, IMP:
6.744 μg/μl, MER: 0.4215 μg/μl, RIF: 107.904 μg/μl, FOS: 13811.712 μg/μl, KAN: 215.808 μg/μl, TIG: 26.976 μg/μl. (B) Percentage of survivals of Group II
injected with isolate IMP53, harboring both blaCTX−M−15 and blaOXA−48 genes, during the monitoring period (p-value = 0.031). The concentration of the bacteria
injected (3x LD50) = 3 × 107 CFU/μl. Concentration of the antimicrobial agents added: COL: 120, ETP: 1920 μg/μl, IMP: 480 μg/μl, MER: 240 μg/μl, RIF:
480 μg/μl, FOS: 30720 μg/μl, KAN: 7680 μg/μl, TIG: 30 μg/μl. (C) Percentage of survivals of Group III injected with isolate IMP216, harboring blaNDM−1 gene,
during the monitoring period (p-value = 0.029). The concentration of the bacteria injected (3x LD50) = 6.48 × 106 CFU/μl. Concentration of the antimicrobial agents
added: COL: 11289.6 μg/μl, ETP: 45158.4 μg/μl, IMP: 90316.8 μg/μl, MER: 5644.8 μg/μl, RIF: 11289.6 μg/μl, FOS: 90316.8 μg/μl, KAN: 1445069 μg/μl, TIG:
352.8 μg/μl. (D) Percentage of survivals of Group IV injected with isolate KPC, harboring the blaKPC−2 gene, during the monitoring period (p-value = 0.043). The
concentration of the bacteria injected (3x LD50) = 3 × 108 CFU/μl. Concentration of the antimicrobial agents added: COL: 1200 μg/μl, ETP: 2400 μg/μl, IMP:
2400 μg/μl, MER: 2400 μg/μl, RIF: 4800 μg/μl, FOS: 4800 μg/μl, KAN: 19200 μg/μl, TIG: 300 μg/μl. TSB, Tryptic Soy Broth; COL, colistin; CAZ, ceftazidime;
ETP, ertapenem; IMP, imipenem; MER, meropenem; KAN, kanamycin; FOS, fosfomycin; and TIG, tigecycline.
2012). In addition, the blaCTX−M−15 gene transcript levels
in isolates IMP33 and IMP53 were diﬀerent; this diﬀerence
might be attributed to the fact that the isolate IMP33 is
a K. pneumoniae, while the isolate IMP53 is an E. coli
isolate.
The diﬀerence between in vitro and in vivo results may
limit the understanding of the eﬃcacy of combination therapy.
These discrepancies could be explained by the fact that in
vivo conditions can trigger diﬀerent mechanisms in bacteria
(Davies et al., 1988). In addition, the eﬀect of the immune
system in the host, the pharmacokinetic and pharmacodynamic
parameters of the antimicrobial agents may explain some
discrepancies between in vitro and in vivo (Chen et al., 2011;
Polak, 2013). In addition, we have the possibility of experimental
variation between the in vitro and the in vivo experimental
setups.
For isolate IMP53 (blaCTX−M−15 and blaOXA−48), an evident
decrease in blaOXA−48 gene transcript levels was observed after
all treatment modes, both in vitro and in vivo (except with colistin
monotherapy). In fact, the MIC levels of IMP53 (blaCTXM−15 and
blaOXA−48), are reported as low level resistance to both imipenem
and meropenem, and susceptible to colistin. Indeed, even though
OXA enzymes confer carbapenem resistance, they exhibit poor
carbapenem and cephalosporin hydrolysis activities (Queenan
and Bush, 2007). As a result, these antimicrobial treatmentsmight
be eﬀective in killing the bacteria, thus explaining the low gene
transcript levels. Another reason might be explained by the fact
that the plasmid harboring the blaOXA−48 gene is associated with
insertion sequences, which provide the carbapenemase encoding
gene with a promoter region that controls its transcription level
(Depardieu et al., 2007; El-Herte et al., 2012). The promoter
involved in this isolate might not be eﬃcient, reﬂecting a decrease
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in the gene transcript levels (Depardieu et al., 2007; El-Herte et al.,
2012).
Concerning the eﬃcacy of combination therapy in vivo,
carbapenem resistance is not necessarily associated with high
pathogenicity or virulence (CDC, 2014), which might explain
the 100% survival rate observed in Group I injected with
isolate IMP33 (blaCTX−M−15) followed by treatment. Moreover,
carbapenem resistance in this isolate is due to ESBL production
and porin loss which represents a lesser clinical threat
than carbapenemase production (Opazo et al., 2012). As a
result, the treatment regimens for such infections caused
by ESBL producing isolates having porin loss, in BALB/c
mice, extend to include colistin in combination with an
adjuvant antimicrobial agent such as a carbapenem, rifampicin,
or kanamycin (fosfomycin or tigecycline remain for severe
infections).
The advisable treatments for infections caused by OXA-
48 producing isolates include: colistin in combination with
an adjuvant such as a carbapenem, rifampicin, fosfomycin,
or tigecycline. Although there are no deﬁnitive clinical data
that demonstrate improved outcomes with combination
versus monotherapy and one trial suggested that colistin
and rifampin combination and colistin monotherapy were
equivalent, infections with multidrug resistant Acinetobacter
and Enterobacteriaceae are associated with high mortality
rates and we are concerned that the use of a single agent is
not adequate, particularly since resistance can develop during
therapy leaving no therapeutic alternatives (Falagas et al.,
2014).
The general concept of colistin used in combination with
other agents (versus colistin monotherapy) appears beneﬁcial in
the mice infected with virulent CRE strains. However, for drugs
that are active against protein synthesis pathways (rifampicin,
tigecycline), while appearing to reduce resistance gene expression
in vitro, were not shown to add clear clinical beneﬁt when used in
combination in vivo, except perhaps colistin with rifampicin for
KPC Salmonella.
The total survival rate for Group III injected with isolate
IMP216 (blaNDM−1) was 100%. Isolate IMP216 was identiﬁed
as extensively drug resistant as it was resistant to all the
tested antimicrobial agents; nevertheless, 83% of the mice in
the positive control subgroups (3–12) survived. Moreover, there
was no signiﬁcant weight loss observed in these subgroups. In
fact, several studies have reported colonization of organisms
harboring the blaNDM−1 gene as part of the fecal ﬂora (Chen
et al., 2011; Samuelsen et al., 2011). This might be explained
by the fact that antimicrobial resistance can be associated
with both a decreased ﬁtness, expressed by impairment of
the bacterial growth in the infected host (Andersson, 2006;
Samuelsen et al., 2011), and a decreased virulence, represented
by diminished invasiveness and higher clearance rates (Skurnik
et al., 2013). Furthermore, the most eﬀective treatment option
for such infections in BALB/c mice, caused by organisms
harboring the blaNDM−1 gene include, and might be limited
to, combination therapy of colistin with either rifampicin,
fosfomycin, or tigecycline. It is worth mentioning that it is
possible that the twoKlebsiella isolates (IMP33 and IMP216) used
in this study, when injected intraperitoneally, are not as lethal
as E. coli (IMP53) or Salmonella (KPC) isolates given by that
route.
Lastly, the mice group that received the KPC isolate
(blaKPC−2) injections followed by treatment, revealed the lowest
survival rates of 66%, and the surviving mice presented clinical
symptoms of illness with clear weight loss and diarrhea,
demonstrating high virulence. This could be due to the fact that
this isolate is of a Salmonella species. Therefore, based on the
survival rates in BALB/c mice, the treatment options for such
infections include colistin in combination with a carbapenem,
fosfomycin, or kanamycin.
However, the treatment regimens that are not recommended
for infections caused by multi-drug resistant Enterobacteriaceae,
include the monotherapies of either rifampicin, tigecycline,
aztreonam, carbapenem, or colistin, and the combination therapy
of a carbapenem with a third generation cephalosporin (Lim
et al., 2011; El-Srougy et al., 2012; Tängdén, 2012; Perez and Van
Duin, 2013; van Duin et al., 2013).
Based on the overall survival rates in our experiments, it
can be concluded that combination therapy is not associated
with increased death rates, as reported previously (El-Srougy
et al., 2012; Tängdén, 2012; Satlin et al., 2014), especially since
treatment with colistin, the selected cornerstone antimicrobial
agent in these treatments, has high reports of neuro/nephro-
toxicities (Lim et al., 2011; Tängdén, 2012; Kmeid et al., 2013).
It should be noted that diﬀerent species used in this study may
exhibit diﬀerent pathogenic eﬀects, which might explain the
diﬀerent results and values.
Conclusion
Based on the gene transcript levels and mice survival rates,
one generalized regimen cannot be administered as an eﬀective
treatment for the various carbapenem resistant isolates; thereby,
stressing the importance of phenotypic/genotypic testing and
the determination of resistance encoding genes for each isolate.
The use of a rationally optimized combination therapy might
lead to better results than monotherapy especially in virulent
strains. This is due to the fact that monotherapy in vivo using
the same resistant strains and ertapenem, as we demonstrated in a
previous unpublished preliminary study, resulted in poor survival
outcome. Moreover, it would noteworthy to indicate that clinical
trials are needed to further assess the eﬃcacy of combination
therapy in humans.
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